Strides Arcolab is currently trading at Rs 422.00, up by 4.70 points or 1.13% from its previous closing of Rs 417.30 on the BSE.
The scrip opened at Rs 422.00 and has touched a high and low of Rs 432.00 and Rs 417.00 respectively. So far 36000 shares were traded on the counter.
The BSE group 'B' stock of face value Rs 10 has touched a 52 week high of Rs 454.90 on 04-Jan-2011 and a 52 week low of Rs 276.25 on 22-Aug-2011.
Last one week high and low of the scrip stood at Rs 437.00 and Rs 404.35 respectively. The current market cap of the company is Rs 2459 crore.
The promoters holding in the company stood at 28.43% while Institutions and Non-Institutions held 52.90% and 18.68% respectively.
Bangalore-based Strides Arcolab is in talks with foreign companies and private equity investors to sell major part of its business. The company, with revenue of around Rs 2,000 crore, will retain its injectables business while selling all its other segments, both in India and abroad, at a deal size that would value the firm at Rs 5,200 crore. Other parts of the business comprising the pharma generics business include contract research and manufacturing services, and intellectual property-led formulations.
The firm’s injectables business earned revenue of close to Rs 800 crore for the 2010 calendar year, while its non-sterile business earned Rs 1,227.9 crore revenue in the same period. Further, the company will also explore selling its businesses overseas, including Australia, Africa and South-East Asia.
Strides Arcolab is a global pharmaceuticals headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceuticals products with an emphasis on sterlite injectables.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: